ARTICLE | Finance

Ebb & Flow

September 8, 2008 7:00 AM UTC

Two of the biggest holders of Amylin stock reduced their positions on Aug. 27, according to SEC filings last Friday. The 27th was the day after Amylin disclosed four additional deaths among diabetes patients who had taken Byetta at some point and subsequently had developed pancreatitis, but whose deaths the company said did not appear to be "directly attributable" to the disease.

Prior to that, on Aug. 18, FDA alerted healthcare professionals of six new reports of acute hemorrhagic or necrotizing pancreatitis, including two deaths, in patients taking Byetta...